Although few studies have been performed in the context of the BCL-2 family in HNSCC, it has been proposed that MCL-1 expression might predict responsiveness to radiotherapy and chemotherapy in locally advanced HNSCC patients [22]. The gene discussed is BCL2; the disease is head and neck squamous cell carcinoma.